Effects of Latrepirdine on beta amyloid clearance, aggregation and neurodegeneration in Alzheimer�s disease

拉曲吡啶对阿尔茨海默病β淀粉样蛋白清除、聚集和神经变性的影响

• 批准号: nhmrc : 1009295
• 负责人: A/Pr Giuseppe Verdile
• 金额: $ 34.18万
• 依托单位: Edith Cowan University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/effects-latrepirdine-beta-alzheimers-disease/109392
• 关键词: Effects; Latrepirdine; beta; amyloid; clearance

Alzheimer's disease (AD) is becoming more common with our growing aged population and currently no treatment exists that halts disease progress. The increasing health costs of AD underscore the need for development of any treatment that will slow or halt AD pathogenesis. By understanding the mechanisms of action of a drug [latrepirdine] that has recently shown some promise in phase II clinical trials, related drugs that are more specific and potent will be developed.

随着老年人口的不断增长，阿尔茨海默病（AD）变得越来越常见，目前还没有任何治疗方法可以阻止疾病的进展。AD日益增加的健康成本强调了开发任何减缓或停止AD发病机制的治疗方法的必要性。通过了解最近在II期临床试验中显示出一些希望的药物[latrepirdine]的作用机制，将开发出更特异性和更有效的相关药物。